A phase 1 study evaluating the safety, tolerability, and pharmacokinetics of the porcupine inhibitor, AZD5055

A phase 1 study evaluating the safety, tolerability, and pharmacokinetics of the porcupine inhibitor, AZD5055

Summary: Excessive Wnt signaling contributes to the development of fibrotic diseases and cancer. Here, we report the findings of a phase 1 study evaluating AZD5055, an orally administered porcupine inhibitor, which inhibits Wnt signaling. The primary objective was to evaluate the safety and tolerabi...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiao-Hong Zhou, Susanne Prothon, Engin Liathdale, Nicola Ferrari, Kebria Hezaveh, Zhi Liu, Szilard Nemes, Joachim Almquist, Michael L. Williams, Olami Sobande, Christer Gottfridsson, Bernadette R. Gochuico, Adam Platt, Zach Brohawn, Maria G. Belvisi, Ronald Goldwater, Ellinor Hornberg, Caroline A. Owen
Format: Article
Language:English
Published: Elsevier 2025-06-01
Series:iScience
Subjects:
Health sciences
Medicine
Medical specialty
Internal medicine
Oncology
Drugs
Online Access:http://www.sciencedirect.com/science/article/pii/S2589004225008636
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2589004225008636

Similar Items